Cargando…
Troponin I levels in permanent atrial fibrillation—impact of rate control and exercise testing
BACKGROUND: High-sensitivity troponin I (hs-TnI) and troponin T (hs-TnT) are moderately correlated and independently related to outcome in atrial fibrillation (AF). Rate controlling therapy has been shown to reduce hs-TnT, however the potential impact on hs-TnI levels, and whether this differs from...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855853/ https://www.ncbi.nlm.nih.gov/pubmed/27142292 http://dx.doi.org/10.1186/s12872-016-0255-x |
_version_ | 1782430425762758656 |
---|---|
author | Horjen, Anja Wiedswang Ulimoen, Sara Reinvik Enger, Steve Norseth, Jon Seljeflot, Ingebjørg Arnesen, Harald Tveit, Arnljot |
author_facet | Horjen, Anja Wiedswang Ulimoen, Sara Reinvik Enger, Steve Norseth, Jon Seljeflot, Ingebjørg Arnesen, Harald Tveit, Arnljot |
author_sort | Horjen, Anja Wiedswang |
collection | PubMed |
description | BACKGROUND: High-sensitivity troponin I (hs-TnI) and troponin T (hs-TnT) are moderately correlated and independently related to outcome in atrial fibrillation (AF). Rate controlling therapy has been shown to reduce hs-TnT, however the potential impact on hs-TnI levels, and whether this differs from the effects on hs-TnT, has not been investigated previously. METHODS: Sixty patients with stable, permanent AF without heart failure or known ischemic heart disease were included in a randomised crossover study (mean age 71 ± 9 years, 18 women). Diltiazem 360 mg, verapamil 240 mg, metoprolol 100 mg, and carvedilol 25 mg were administered once daily for three weeks, in a randomised sequence. At baseline and on the last day of each treatment period, hs-TnI was measured at rest and after a maximal exercise test and compared to hs-TnT. RESULTS: Hs-TnI and hs-TnT correlated moderately at baseline (r(s) = 0.582, p < 0.001). All drugs reduced both the resting and the peak exercise levels of hs-TnI compared with baseline (p < 0.001 for all). The decline in resting hs-TnI and hs-TnT values relative to baseline levels was similar for all drugs except for verapamil, which reduced hs-TnI more than hs-TnT (p = 0.017). Levels of hs-TnI increased significantly in response to exercise testing at baseline and at all treatment regimens (p < 0.001 for all). The relative exercise-induced increase in hs-TnI was significantly larger compared to hs-TnT at baseline (p < 0.001), on diltiazem (p < 0.001) and on verapamil (p = 0.001). CONCLUSIONS: In our population of stable, permanent AF patients, all four rate control drug regimens reduced hs-TnI significantly, both at rest and during exercise. The decline in hs-TnI and hs-TnT levels associated with beta-blocker and calcium channel blocker treatment was similar, except for a larger relative decrease in hs-TnI levels following verapamil treatment. TRIAL REGISTRATION: www.clinicaltrials.gov (NCT00313157). |
format | Online Article Text |
id | pubmed-4855853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-48558532016-05-05 Troponin I levels in permanent atrial fibrillation—impact of rate control and exercise testing Horjen, Anja Wiedswang Ulimoen, Sara Reinvik Enger, Steve Norseth, Jon Seljeflot, Ingebjørg Arnesen, Harald Tveit, Arnljot BMC Cardiovasc Disord Research Article BACKGROUND: High-sensitivity troponin I (hs-TnI) and troponin T (hs-TnT) are moderately correlated and independently related to outcome in atrial fibrillation (AF). Rate controlling therapy has been shown to reduce hs-TnT, however the potential impact on hs-TnI levels, and whether this differs from the effects on hs-TnT, has not been investigated previously. METHODS: Sixty patients with stable, permanent AF without heart failure or known ischemic heart disease were included in a randomised crossover study (mean age 71 ± 9 years, 18 women). Diltiazem 360 mg, verapamil 240 mg, metoprolol 100 mg, and carvedilol 25 mg were administered once daily for three weeks, in a randomised sequence. At baseline and on the last day of each treatment period, hs-TnI was measured at rest and after a maximal exercise test and compared to hs-TnT. RESULTS: Hs-TnI and hs-TnT correlated moderately at baseline (r(s) = 0.582, p < 0.001). All drugs reduced both the resting and the peak exercise levels of hs-TnI compared with baseline (p < 0.001 for all). The decline in resting hs-TnI and hs-TnT values relative to baseline levels was similar for all drugs except for verapamil, which reduced hs-TnI more than hs-TnT (p = 0.017). Levels of hs-TnI increased significantly in response to exercise testing at baseline and at all treatment regimens (p < 0.001 for all). The relative exercise-induced increase in hs-TnI was significantly larger compared to hs-TnT at baseline (p < 0.001), on diltiazem (p < 0.001) and on verapamil (p = 0.001). CONCLUSIONS: In our population of stable, permanent AF patients, all four rate control drug regimens reduced hs-TnI significantly, both at rest and during exercise. The decline in hs-TnI and hs-TnT levels associated with beta-blocker and calcium channel blocker treatment was similar, except for a larger relative decrease in hs-TnI levels following verapamil treatment. TRIAL REGISTRATION: www.clinicaltrials.gov (NCT00313157). BioMed Central 2016-05-04 /pmc/articles/PMC4855853/ /pubmed/27142292 http://dx.doi.org/10.1186/s12872-016-0255-x Text en © Horjen et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Horjen, Anja Wiedswang Ulimoen, Sara Reinvik Enger, Steve Norseth, Jon Seljeflot, Ingebjørg Arnesen, Harald Tveit, Arnljot Troponin I levels in permanent atrial fibrillation—impact of rate control and exercise testing |
title | Troponin I levels in permanent atrial fibrillation—impact of rate control and exercise testing |
title_full | Troponin I levels in permanent atrial fibrillation—impact of rate control and exercise testing |
title_fullStr | Troponin I levels in permanent atrial fibrillation—impact of rate control and exercise testing |
title_full_unstemmed | Troponin I levels in permanent atrial fibrillation—impact of rate control and exercise testing |
title_short | Troponin I levels in permanent atrial fibrillation—impact of rate control and exercise testing |
title_sort | troponin i levels in permanent atrial fibrillation—impact of rate control and exercise testing |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855853/ https://www.ncbi.nlm.nih.gov/pubmed/27142292 http://dx.doi.org/10.1186/s12872-016-0255-x |
work_keys_str_mv | AT horjenanjawiedswang troponinilevelsinpermanentatrialfibrillationimpactofratecontrolandexercisetesting AT ulimoensarareinvik troponinilevelsinpermanentatrialfibrillationimpactofratecontrolandexercisetesting AT engersteve troponinilevelsinpermanentatrialfibrillationimpactofratecontrolandexercisetesting AT norsethjon troponinilevelsinpermanentatrialfibrillationimpactofratecontrolandexercisetesting AT seljeflotingebjørg troponinilevelsinpermanentatrialfibrillationimpactofratecontrolandexercisetesting AT arnesenharald troponinilevelsinpermanentatrialfibrillationimpactofratecontrolandexercisetesting AT tveitarnljot troponinilevelsinpermanentatrialfibrillationimpactofratecontrolandexercisetesting |